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The heat-shock response, one of the main pro-survival mechanisms of a living organism, 
has evolved as the biochemical response of cells to cope with heat stress. The most 
well-characterized aspect of the heat-shock response is the accumulation of a conserved 
set of proteins termed heat-shock proteins (HSPs). HSPs are key players in protein 
homeostasis acting as chaperones by aiding the folding and assembly of nascent 
proteins and protecting against protein aggregation. HSPs have been associated with 
neurological diseases in the context of their chaperone activity, as they were found to 
suppress the aggregation of misfolded toxic proteins. In recent times, HSPs have proven 
to have functions apart from the classical molecular chaperoning in that they play a role in 
a wider scale of neurological disorders by modulating neuronal survival, inflammation, and 
disease-specific signaling processes. HSPs are gaining importance based on their ability 
to fine-tune inflammation and act as immune modulators in various bodily fluids. However, 
their effect on neuroinflammation processes is not yet fully understood. In this review, we 
summarize the role of neuroinflammation in acute and chronic pathological conditions 
affecting the brain. Moreover, we seek to explore the existing literature on HSP-mediated 
inflammatory function within the central nervous system and compare the function of 
these proteins when they are localized intracellularly compared to being present in the 
extracellular milieu.
Keywords: neuroinflammation, heat shock proteins, heat shock response, diseases of the central nervous system, 
extracellular heat shock proteins, inflammation modulation
INTRODUCTION
Neuroinflammation is a well-known feature of different acute brain disorders including ischemic 
stroke, traumatic brain injury, and chronic neurodegenerative diseases such as Alzheimer’s (AD) 
and Parkinson’s (PD) diseases (Kim and Yenari, 2013; Banjara and Ghosh, 2017). It is characterized 
by an increased level of cytokines and chemokines with concomitant activation of glial cells and the 
infiltration of leukocytes (Kim and Yenari, 2013).
Activation of the inflammatory cascades within these cells is mediated by specialized pattern-
recognition receptors (PRRs) like toll-like receptors (TLRs) and NOD-like receptors (Banjara and 
Ghosh, 2017). PRRs recognize different danger signals triggering immune response. These danger 
signals can be external, mainly pathogen-derived molecules (pathogen-associated molecular 
patterns-PAMPs). On the other hand, tissue injury after ischemic stroke or during chronic 
neurodegenerative diseases can lead to sterile inflammation. In these conditions, the release of 
endogenous damage–associated molecules (danger-associated molecular pattern-DAMP) activates 
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the inflammatory cascade (Banjara and Ghosh, 2017). DAMPs 
could flow out from necrotic cells or they can be secreted 
specifically by damaged cells to trigger the immune response to 
clean cell debris and initiate tissue repair (Giuliano et al., 2011).
DAMPs are very diverse regarding their origin and chemical 
properties. They include uric acid, extracellular ATP, 
mitochondrial DNA, misfolded proteins like β-amyloid (Aβ), 
glycoproteins, hormones, and extracellular RNA (Patel, 2018). 
Moreover, heat-shock proteins (HSPs) appear to be ideal 
DAMPs, as they are highly conserved molecules, one of the 
most abundant intracellular proteins whose expression is further 
increased upon tissue injury like thermal or oxidative stress or 
in response to infections. As molecular chaperones, HSPs are 
able to bind several peptides suggesting that they can be involved 
in antigen presentation. Moreover, HSPs themselves are able to 
trigger the inflammatory response (Giuliano et al., 2011).
DAMPs can bind to the PRRs of microglia and other immune 
cells leading to the stimulation of inflammatory cascades by the 
activation of different pro-inflammatory transcription factors 
like nuclear factor kappa B (NF-κB) (Kim and Yenari, 2013; 
Banjara and Ghosh, 2017). Under normal conditions, the inactive 
heterodimeric NF-κB is bound by its inhibitor NF-κB inhibitor 
beta (IkB) in the cytosol. Activation of the inflammatory cascade 
results in the phosphorylation and degradation of IkB, releasing 
NF-κB. The activated transcription factor then moves to the 
nucleus, initiating the expression of several inflammatory factors 
like cytokines and chemokines (Kim and Yenari, 2013).
The condition of the brain tissue is constantly monitored by 
glial cells, primarily microglia and astrocytes (Banjara and Ghosh, 
2017). Brain-resident microglia cells are the first responders 
to central nervous system (CNS) damage; they accumulate 
within a short period of time in the injured area and begin the 
phagocytic removal of myelin debris, which is important because 
this debris can release axonal regrowth–inhibiting factors. 
Moreover, activated microglia also play an important role in glial 
scar formation and in support of the blood–brain barrier (BBB) 
(Mosley and Cuzner, 1996; Schwab, 2004; Davalos et al., 2005; 
Lou et al., 2016; Xu et al., 2019). However, through their TLRs, 
DAMPs activate the pro-inflammatory phenotype of microglia 
besides the early phagocytic phenotype, which is destructive to 
the brain tissue since it can produce pro-inflammatory cytokines, 
chemokines, complement system components, free radicals, 
and matrix metalloproteases (MMPs) which could result in 
an increase in BBB permeability and apoptosis (Walker et al., 
1995; Jack et al., 2005; Yenari et al., 2006; del Zoppo et al., 2012; 
Kawabori and Yenari, 2015). Activation of microglia is the first 
step in the inflammatory response of the brain, followed by 
the activation and proliferation of astrocytes, contributing to 
an even more robust secretion of pro-inflammatory signaling 
molecules (Banjara and Ghosh, 2017). The released chemokines 
play a major role in the activation of peripheral immune cells 
(Glabinski et al., 1995). In response to inflammatory factors, 
neutrophils rapidly infiltrate into the affected brain areas. Like 
glia, they produce inflammatory mediators and reactive oxygen 
species and can be the source of high MMP levels in the injured 
area, thereby enhancing neurotoxicity, contributing to vascular 
permeability, and causing cerebral edema. On the other hand, 
by phagocytosis and production of growth factors, neutrophils 
can also take part in restoration of the damaged area (Schoettle 
et al., 1990; Soares et al., 1995; Nguyen et al., 2007; Rosell et al., 
2008; Liu et al., 2018a). Peripheral monocytes are also able 
to enter the brain parenchyma a few hours after injury. When 
the peripheral monocyte encounters traumatized or infected 
tissue, it is differentiated into a macrophage or a dendritic cell. 
The infiltrating macrophages are primarily cytotoxic, but their 
function can vary depending on whether the pro- or the anti-
inflammatory phenotype is dominant; therefore, they can have 
a role in phagocytosis, cytokine/chemokine release, antigen 
presentation, astroglial scar formation, and tissue repair (Girard 
et al., 2013; Vogel et al., 2014; Gliem et al., 2016; Frik et al., 
2018; Malo et al., 2018). Dendritic cells are important in both 
innate and adaptive immune responses, but their predominant 
role is antigen presenting by which antigen-specific T cells are 
being activated and migrated into the brain (Felger et al., 2010; 
Malo et al., 2018). Thus, the switch from non-specific innate 
immune response to the adaptive response is triggered by the 
appearance of T cells, which are activated via antigens presented 
by dendritic cells, macrophages, and microglia. Different types 
of T lymphocytes have different roles. CD4 + (“helper”) T cells 
control the adaptive immune response, while CD8 + (“killer”) 
T  cells kill infected and damaged cells. T-cell infiltration after 
injury is mostly neurotoxic: it releases interferon gamma (INFγ) 
and other inflammatory cytokines, but it can also have a protective 
role. T regulatory cells can protect against inflammation in many 
ways, including expression of tumor growth factor beta (TGF-β) 
and interleukin-10 (IL-10) (Ford et al., 1996; Liesz et al., 2009; 
Gill and Veltkamp, 2016; Malo et al., 2018).
Role of Neuroinflammation in Different 
Acute and Chronic CNS Diseases
Inflammation has a key role in most acute and neurodegenerative 
CNS disorders. However, it is complicated to define if 
inflammation is a cause or consequence of neuronal cell death in 
different CNS diseases. Neuroinflammation can naturally occur 
in response to many acute damaging effects, such as pathogenic 
invasion or tissue injury being the first line of defense of the 
brain tissue (Swaroop et al., 2016; Banjara and Ghosh, 2017). 
Activated immune cells combat against pathogens and eliminate 
damaged tissue, thereby, preventing the spread of infection 
and necrosis. However, we should not neglect the Janus-faced 
nature of inflammation. In addition to protective functions, an 
excessive, over-activated inflammatory response may lead to 
further neuronal damage (reviewed recently in Le et al., 2016; 
Banjara and Ghosh, 2017; Sochocka et al., 2017). In the case of 
chronic, age-related neurodegenerative diseases, inflammation 
seems to have a central role in the pathology of the disease. 
Since the development of these disorders is a slow process, the 
underlying pathophysiological mechanisms induce a constant 
immune response in the brain, leading to chronic inflammation. 
While a rapid, acute course of inflammation which induces an 
immune reaction within a relatively short period of time can 
have beneficial effects, prolonged inflammation triggered by 
continuously present insults usually leads to the destruction of 
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brain tissue. Additionally, persistent activation interferes with the 
normal, beneficial housekeeping functions of resident cells of the 
brain, such as microglia and astrocytes. Although these cells can 
be involved in the elimination of pathological protein aggregates, 
they go through cellular senescence with age and are less able to 
perform their physiological functions (Floden and Combs, 2011; 
Caldeira et al., 2017; Gomez-Arboledas et al., 2018). Along with 
aging, the integrity of the vascular network also decreases (Elahy 
et al., 2015; Montagne et al., 2015), allowing systemic immune 
processes to affect the brain, which is in turn no longer immune-
privileged. These processes could lead to the dysregulation of 
immune mechanisms in the CNS and to the development of a 
pro-inflammatory milieu, which could advance the progression 
of neurological diseases and neurodegeneration (reviewed in 
Costantini et al., 2018).
The tissue injury caused by acute, sterile brain-damaging 
conditions like ischemic stroke and by traumatic brain injury 
could be very similar to each other. After cerebral artery 
occlusion, a core region is formed where the blood flow ceases 
and the subsequent glucose and oxygen deficiency completely 
eliminate the neurons and glial cells. This is surrounded by a 
so-called penumbra, where there is still a limited blood perfusion 
which already damages the cells but does not lead to cell death 
(Zhang et al., 1997; Lee et al., 2000). Similarly, in the traumatized 
brain area, hypoperfusion and local ischemia also develop. In 
both cases, the impacts are followed by reperfusion, which is 
indispensable in the restoration of brain oxygen and nutrient 
supply, yet causes inflammatory processes and secondary tissue 
damage (Coles, 2004; Lin et al., 2016). After injury, the amount 
of the two major pro-inflammatory cytokines, IL-1β and tumor 
necrosis factor (TNF)-α, increases in the core and penumbra 
regions after a few hours by expression of resident CNS cells. 
This activates additional microglia and astrocyte cells, increases 
the production of chemokines, the level of apoptosis, the 
permeability of the BBB, and edema formation (Feuerstein et al., 
1994; Sairanen et al., 2001; Rothwell, 2003; Hosomi et al., 2005; 
Lu et al., 2005; Sozen et al., 2009). Under experimental conditions 
of stroke and traumatic brain injury, the suppression of pro-
inflammatory cytokines could prevent the loss of interneurons 
and oligodendrocytes, reduce the infarct area, thereby alleviating 
cognitive impairment, and also affect the efficacy of repair 
mechanisms in the long term (Scherbel et al., 1999; Flygt et al., 
2018; Newell et al., 2018; Wang et al., 2018a; Wong et al., 2019). 
In addition to the therapeutic inhibition of pro-inflammatory 
cytokines, the targeting of anti-inflammatory cytokines could also 
be potentially relevant in the therapy of neurological diseases. In 
animal experiments, IL-10 administration decreased the size of 
the infarct area after middle cerebral artery occlusion and down-
regulated pro-inflammatory signaling, while following traumatic 
brain injury, it also reduced TNF-α and IL-1 levels and increased 
neural repair processes (Knoblach and Faden, 1998; Spera et al., 
1998; Liesz et al., 2014).
Recently, a potential neuroprotective role for microglial 
cells was described when the inhibition of microglia has led to 
increased astrocyte activation and increased infarct size by 60% 
after focal brain injury (Szalay et al., 2016; Jin et al., 2017). The 
role of microglia in brain injury could be dual, as they are able to 
form a barrier between the injured and healthy tissue with their 
projections and support the glia limitans (Davalos et al., 2005; 
Roth et al., 2014), while activated microglial cells have been 
shown to be neurotoxic and to induce apoptosis and exacerbate 
inflammatory processes in other studies (Kaushal and Schlichter, 
2008; Hu et al., 2012; Figure 1A).
Acute trauma reduces the integrity of the cerebral 
microvascular network (Chodobski et al., 2011). In addition, 
the released chemokines facilitate the entry of neutrophils, 
monocytes, and T cells (Dimitrijevic et al., 2007; Llovera et al., 
2017). Experimental data from numerous studies have confirmed 
that the influx of neutrophils and monocytes is predominantly 
pro-inflammatory and harmful. For example, after intracerebral 
hemorrhage formation, neutrophils were shown to contribute 
to MMP-9-mediated BBB damage, to white matter destruction, 
and to the increased damaging effect of glial cells to the brain 
(Moxon-Emre and Schlichter, 2011). However, it is important 
that peripheral macrophages with high phagocytic capacity also 
appear 72 h after middle cerebral artery occlusion (Ritzel et al., 
2015). Their beneficial role is demonstrated by the fact that, 
after ischemia, the use of the chemokine receptor type 2 (CCR2) 
antibody reduced the level of anti-inflammatory cytokines 
and long-term repair processes (Wattananit et al., 2016). The 
appearance of T cells in the acute phase exacerbates brain 
damage; accordingly, T cells are crucial to the development of 
secondary neurodegeneration. This is supported by experiments, 
in which the inhibition of IL-17 produced by γδ T-cells, or IL-21 
expressed by CD4+ T-cells successfully reduced the infarct 
size and protected against middle cerebral artery occlusion 
(Clarkson et al., 2014; Arunachalam et al., 2017). On the other 
hand, regulatory T cells activated in later phase were proved to 
be protective. In an animal model of stroke, regulatory T cells 
reduced the level of astrocyte activation and increased the 
production of anti-inflammatory cytokines (Ito et al., 2019).
In many age-related neurodegenerative disorders, aggregation-
prone proteins accumulate in neurons, such as Aβ and tau in AD, 
α-synuclein in PD or huntingtin in Huntington’s disease (HD). 
These proteins tend to form insoluble inclusion bodies within the 
brain tissue, which can initiate a chronic inflammatory response 
(Khandelwal et al., 2011; Yang et al., 2017). The importance of the 
role of inflammation and microglia function in the pathogenesis 
of neurodegenerative diseases is supported by large-scale genetic 
studies (Malik et al., 2015; Gelders et al., 2018). Several single 
nucleotide polymorphisms have been identified associated with 
AD in genes related to microglial phagocytosis or the complement 
system, such as ABCA7, CD33, and CR1 (Lambert et al., 2009; 
Hollingworth et al., 2011; Naj et al., 2011). A missense mutation 
in the gene expressing triggering receptor expressed on myeloid 
cells 2 (TREM2) was found to be a significant risk factor not only 
for AD (Jonsson et al., 2013) but for frontotemporal dementia 
and PD as well (Rayaprolu et al., 2013). TREM2 is involved in 
the activation of microglial phagocytosis without the increase 
of cytokine production; therefore, it can possibly stimulate the 
elimination of Aβ plaques and apoptotic neurons (Rayaprolu 
et al., 2013; Savage et al., 2015). In the brain of AD patients, 
microglia were proved to migrate toward the amyloid plaques 
and to become more stimulated by binding to Aβ. This sustained 
Heat Shock Proteins in NeuroinflammationDukay et al.
4 August 2019 | Volume 10 | Article 920Frontiers in Pharmacology | www.frontiersin.org
microglia activation results in the impairment of microglial 
functions, like motility and phagocytosis, lowering their ability 
to eliminate these toxic protein aggregates from the brain (Su 
et al., 2008; Stewart et al., 2010; Krabbe et al., 2013). In line with 
the loss of their phagocytic capacity by decreased scavenger 
receptors and amyloid-degrading enzymes, the productivity of 
inflammatory cytokines further increased in an aged APP/PS1 
animal model of AD. This negative correlation between the 
expressions of IL-1β, TNF-α, and Aβ clearance generates neuronal 
damage (Hickman et al., 2008; Figure 1B). Earlier results showed 
that IL-1β expression can further stimulate the synthesis and 
cleavage of amyloid precursor protein, leading to Aβ deposition, 
which activates the vicious cycle of Aβ-induced inflammation 
(Goldgaber et al., 1989; Buxbaum et al., 1992). Although in the 
3xTg-AD model, microglial activation by IL-1β was shown to 
be useful in removing amyloid plaques; at the same time, it also 
increased the neurotoxicity of the tau protein (Ghosh et al., 2013). 
Extracellularly secreted hyperphosphorylated tau can also trigger 
the activation of microglia and astrocytes with a concomitant 
increase of cytokine release (reviewed in Laurent et  al., 2018). 
In turn, the increased inflammation and glia activation were 
shown to provoke tau hyperphosphorylation exacerbating 
tau neuropathology in 3xTg-AD mice (Kitazawa et  al., 2005). 
Activated microglial cells with decreased ramification have been 
detected in the brain of HD patients and in the YAC128 mouse 
model of the disease as well (Politis et al., 2011; Franciosi et al., 
2012). In vitro and transgenic mouse studies showed that healthy 
microglia can help to remove dysfunctional neuronal cells and 
restrain the progression of the disease (Kraft et al., 2012; Benraiss 
et al., 2016). In contrast, transplantation of mutant huntingtin-
expressing human glial cells into normal mice worsened their 
motoric performance (Benraiss et al., 2016). These results suggest 
that, similarly to AD and PD, abnormal microglial function has a 
crucial role in the pathogenesis of HD.
In addition, the inflammasomes of infiltrating monocytes and 
in microglia can be activated by Aβ, which further enhances the 
production of IL-1β and IL-18 (Halle et al., 2008; Saresella et al., 
2016). TNF-α was also shown to be elevated in the cerebrospinal 
FIGURE 1 | The role of microglia in acute and chronic inflammations. (A) Under normal circumstances, the brain tissue is constantly monitored by resting microglia 
cells (1). Acute brain damage triggers dynamic microglia activation. This is a linear process that will decline over time (2). First, an early phagocytic phenotype 
accumulates in the injured area and begins to remove the debris (3). However, the majority of microglia rapidly converts to a pro-inflammatory phenotype via 
classical activation, which is neurotoxic, induces apoptosis and exacerbates inflammatory processes (4). At the same time, some microglia get alternatively activated 
and exert a neuroprotective effect to counteract the pro-inflammatory processes (5). After the resolution of the inflammatory cascades, microglia return to resting 
state and continue the tissue surveillance (6). (B) Due to physiological aging, the basic activation state of microglia is increased (2), which is associated with elevated 
production of cytokines and inflammatory mediators. These so-called primed microglia cells show an elevated responsiveness (3) and potentially can be more 
stimulated by binding disease-associated proteins and other toxic agents (4). The over-activation results in the impairment of certain microglial functions lowering 
their ability to eliminate the toxic protein aggregates; however, in line with their phagocytic dysfunction, their productivity of inflammatory cytokines further increases 
(5). This negative correlation between the expression of pro-inflammatory cytokines and the clearance of abnormal proteins generates the vicious cycle of chronic 
inflammation, which is a characteristic of neurodegenerative diseases (6).
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fluid of AD patients and was described to be a risk factor in PD 
(Tarkowski et al., 2003; Lindenau et al., 2017). In the APP23 
transgenic mouse model of AD, suppression of the TNF-α 
receptor 1 diminished Aβ production and plaque formation by 
reducing BACE1 activity, which, in parallel, reduced disease-
associated cognitive dysfunctions (He et al., 2007). The role of 
the anti-inflammatory IL-10 is controversial, as its elevated 
expression lowers the level of pro-inflammatory cytokines and 
chemokines, which is important for restoring immune balance, 
yet in excess, it restrains the activated microglia around plaques 
causing reduced Aβ phagocytosis (Szczepanik et al., 2001; 
Guillot-Sestier et al., 2015).
Beside microglia, astrocytes can also contribute to the 
neurotoxicity triggered by disease-associated proteins. In the 
brain of AD and PD patients, reactive astrogliosis appears, and 
its distribution is associated with the presence of α-synuclein 
containing Lewis bodies and Aβ senile plaques (Braak et al., 2007; 
Medeiros and LaFerla, 2013). Since astrocytes take part in the 
formation of the BBB, their activation in old mice compared to 
young ones promoted barrier dysfunction, which occurs during 
normal ageing, increasing the risk of disease development (Elahy 
et al., 2015). Primary astrocytes isolated from AD mice showed 
a highly induced BACE-1 expression and amyloid precursor 
protein secretion upon IFNγ treatment, presuming the role of 
astrocytes in amyloidosis (Hong et al., 2003). In contrast, a study 
in which wild-type astrocytes were transplanted into the brain 
of a mouse with AD demonstrates the capacity of astrocytes to 
degrade Aβ (Pihlaja et al., 2011). In PDGF α-synuclein transgenic 
mice, astrocytes took up neuronal cell-derived α-synuclein 
which stimulated the release of pro-inflammatory cytokines, 
chemokines, and other inflammatory mediators (Lee et al., 2010).
Peripheral immune cells, like macrophages, were shown 
to assemble around Aβ deposits to eliminate them in the 
mouse model of AD. Furthermore, in different models of AD, 
an increased load of amyloid occurred after the restriction of 
mononuclear phagocyte infiltration into the brain or with the 
removal of CD11b+ macrophages from the parenchyma (Simard 
et al., 2006; El Khoury et al., 2007). In contrast, macrophages from 
AD patients presented a limited internalization of Aβ, suggesting 
a phagocytic dysfunction compared to the control macrophages 
(Fiala et al., 2005). It has been reported that the lack of CD36, 
which is needed for amyloid binding and which cooperates with 
TLR4 and TLR6 receptors, attenuated Aβ accumulation and 
NLRP3 activation in macrophages (Sheedy et al., 2013). The 
adaptive immune system is also involved in the pathogenesis of 
neurodegeneration, which is demonstrated by the elevated level 
of Aβ-reactive T-cells in AD patients and even in healthy elderly 
humans and by the α-synuclein specific T-cell response in PD 
(Monsonego et al., 2003; Sulzer et al., 2017). In PD patients, 
well-characterized parts of the α-synuclein were recognized as 
epitopes which mostly stimulated the IL-5-expressing CD4+ 
cells and the cytotoxic IFNγ-producing CD8+ cells; moreover, 
the activation of CD4+ T-cells was accompanied by the injury of 
dopaminergic neurons (Brochard et al., 2009; Sulzer et al., 2017).
These results show that, after acute injuries, the immune 
cells are rapidly activated in order to eliminate cellular debris; 
however, the immune response should be mitigated in the right 
time, as the excessive cytokine release could promote further 
neuronal damage. In chronic neurodegenerative diseases, the 
toxic protein aggregates are generated persistently inducing a 
chronic immune response. Microglial and macrophage cells are 
assumed to clear the protein inclusions; however, during aging 
and in neurodegenerative diseases, their phagocytic activity 
declines due to cellular senescence (Luo et al., 2010; Costantini 
et al., 2018), while there is an increase in cytokine production. 
Taken together, it seems that both the lack and exaggeration 
of inflammatory responses can promote neuronal damage; 
therefore, it should be tightly regulated. In the next sections, we 
attempt to summarize the immunomodulatory roles of HSPs. 
Many evidences suggest that HSPs have several moonlighting 
functions through which they can be involved in the regulation 
of immune cell activity and cytokine release. Therefore, the 
modulation of HSP levels could serve as potential therapeutic 
applications to treat CNS diseases related to inflammation.
Intracellular HSPs and the Heat-Shock 
Response
Living organisms can be subjected to environmentally 
constrained challenges. To survive, they have to counter these 
unfavorable conditions by adaptation. The term cellular stress 
response summarizes universal cellular reactions to a wide 
variety of environmental challenges (Kültz, 2005). Among the 
many cellular survival mechanisms, the response to heat stress is 
amongst the most ancient and conserved (Horváth et al., 2008). 
Heat stress induces multi-leveled signaling in cellular systems 
termed as the heat-shock response. The heat-shock response 
was originally defined as the biochemical response of cells to 
heat stress (Lindquist, 1986). Although it has been primarily 
described to be induced by increased temperatures, it has also 
been recognized that the heat-shock response can be activated by 
a wider range of cellular stressors like membrane perturbations, 
heavy metals, oxidative stress, or by pathophysiological 
conditions (Morimoto, 1998; Vigh et al., 2007; Balogh et al., 
2013). One of the most characterized aspects of the heat-shock 
response is the accumulation of a conserved set of HSPs. HSPs 
primarily act as chaperones within the cell by aiding the folding 
of proteins, the refolding of denatured proteins, and by guiding 
the degradation of irreversibly damaged proteins. Therefore, 
HSPs are involved in the maintenance of protein homeostasis 
by alleviating the unfavorable changes caused by heat stress 
(Kampinga, 2006). HSPs consist of many different families 
differentiated by their molecular weight. In 2009, Kampinga and 
co-workers proposed a new nomenclature of human HSP families 
(Kampinga et al., 2009). Small HSPs (sHSPs) are the most diverse 
set of HSPs, consisting of proteins within a 12–43 kDa range. 
They can form multimeric complexes and display a wide range 
of cellular functions. The sHSPs coaggregate with aggregation-
prone proteins to initiate efficient disaggregation. The release of 
substrate proteins from the transient sHSP reservoirs and their 
refolding require cooperation with ATP-dependent chaperone 
systems (Van Montfort et al., 2001). The sHSP holdase, HSPB1, 
can form large oligomeric structures which can act as molecular 
chaperones sequestering unfolded proteins and inhibiting 
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subsequent aggregation and insolubilization (Singh et al., 
2017). HSPB1 is additionally involved in actin polymerization/
depolymerization (Tang, 2015). HSPD1 is an ATP-dependent 
unfoldase. The HSPD1 proteins in eukaryotes are localized to 
the mitochondria and are responsible for mitochondrial protein 
import and macromolecular assembly within this compartment 
(Koll et al., 1992). HSPA1 is most likely the best-characterized 
chaperone. The HSPA proteins act together with their many 
co-chaperones, working as a “HSPA chaperone machinery” 
(Kampinga and Craig, 2010). The most important co-chaperones 
are the DNAJ family and the nucleotide exchange factors. DNAJ 
proteins exhibit great diversity; however, all of them include a 
conserved J domain required for its binding to HSPA1 (Hennessy 
et al., 2005). DNAJ takes part in the substrate specificity of 
HSPA1 and can increase the ATPase activity of the HSPA1 
protein thereby enhancing their activity. The nucleotide exchange 
factors promote the dissociation of the ADP from HSPA1. This 
ATPase cycle regulates the binding and release of the substrate, 
since HSPA proteins have a higher affinity for unfolded proteins 
when bound to ADP, and a lower affinity when bound to ATP 
(Mayer and Bukau, 2005). The HSPA1/DNAJ system participates 
in the active ATP-dependent folding-refolding of a high number 
of cellular proteins. On the other hand, the non-refoldable 
substrates can be selected to proteasomal degradation, which 
process is mediated by ubiquitin ligases as the CHIP E3 ligase 
(VanPelt and Page, 2017). HSPC1 is also an ATP-dependent 
chaperone which facilitates the maturation and/or activation 
of many “client proteins” involved in signal transduction and 
transcriptional regulation and is necessary for viability in 
eukaryotes. HSPC1 is central to processes broadly ranging from 
cell cycle regulation to protein degradation, and it has also been 
connected with cellular transformation (Brown et al., 2007). 
Therefore, the potential utilization of specific inhibitors of 
HSPC1 for cancer treatment has long been investigated (Schopf 
et al., 2017; Zuehlke et al., 2018). The proteins in the HSPH 
family form large hexameric structures with an unfoldase activity 
in the presence of ATP. These proteins are considered to function 
as chaperones by recessively threading client proteins through a 
small pore, thereby providing each client protein with a second 
chance to fold (Schirmer et al., 1996).
The expression of HSPs occurs under strong transcriptional 
control. Among eukaryotes, the transcriptional activation of HSP 
genes is regulated by the family of transcriptional factors termed 
as heat-shock factors (HSFs). The family consists of four different 
HSFs, from which HSF1 is the main transcriptional regulator 
of the HSP genes (Richter et al., 2010). HSF1 is constitutively 
present in its inactive form in most tissues and cell types in the 
cytosol. Under stress conditions, HSF1 undergoes a multistep 
activation process as the cytosolic HSF1 dissociates from HSPA/
HSPC which prevents the interaction of HSF1 monomers. HSF1 
trimerizes and subsequently translocates to the nucleus and 
binds to extended repeats of the sequence nGAAn, termed as 
heat-shock elements, in the promoter regions of its target genes 
(Morimoto, 1998). Moreover, in addition to activating the heat-
shock response, HSF1 is involved in the regulation of many 
other cellular processes. HSF1 is able to modulate not only the 
HSP expression but the transcription of other genes as well—for 
example, it is involved in the regulation of apoptotic cell death, 
autophagy, the immune response, aging, or even synaptic 
function (Hooper et al., 2016; Barna et al., 2018). Several studies 
demonstrated that HSF1 is necessary for the normal function 
of the immune system, and it can regulate the expression of 
different inflammatory cytokines and chemokines, although its 
exact effect has not been fully elucidated yet (Barna et al., 2018).
HSF1 was first suggested to play a role in inflammatory 
processes when an abundant increase in the pro-inflammatory 
cytokine TNF-α was observed upon treatment with bacterial 
lipopolysaccharides (LPS) in HSF1 knockout mice (Xiao et al., 
1999). This observation later led to the discovery of the inhibitory 
regulation of HSF1 over TNF-α by its binding to elements in the 
promoter (Singh et al., 2002), suggesting an intertwined close 
regulation between TNF-α signaling and HSF1. In contrast, a 
recent study showed that heat-shock treatment can induce the 
expression of TNF-α independently from NF-κB signaling. The 
transcription of TNF-α was activated by a multiprotein complex 
containing HSF1 (Ali et al., 2019), suggesting that the effect of 
HSF1 on TNF-α expression is likely to be influenced by other 
factors as well. Another level of interplay has been revealed 
between heat shock and TNF-mediated inflammatory signaling 
when TNF-α was described to cause downregulation of HSF1 
activation, which was shown to increase apoptotic cell death 
(Schett et al., 2003). Furthermore, it has been demonstrated 
that heat pretreatment decreases LPS-induced IL-6 expression 
in macrophages and mouse embryonic ﬁbroblast cells. The 
heat-induced HSF1 upregulated the ATF3 transcription factor, 
a negative regulator of IL-6 expression (Takii et al., 2010). This 
was a surprising result, as it was previously observed that HSF1 
is necessary for the maximal induction of IL-6 in response to 
LPS treatment without heat shock (Inouye et al., 2007). Under 
non-stressful conditions, the HSF1 was found to bind directly to 
IL-6 promoter and, by promoting the opening of the chromatin 
structure, it may help the access of activator or repressor regulatory 
molecules (Inouye et al., 2007). However, the IL-6 expression of 
many tissues and the serum level of IL-6 were higher in HSF 
null-mutant mice compared to wild types after LPS injection, 
suggesting an inhibitory role of HSF1 on IL-6 production in vivo 
(Takii et al., 2010). Heat-shock elements can be found in the 
promoter region of CXC chemokine genes as well, although a 
heat shock has gene-specific enhancing or repressing effect on 
the expression of these genes (Maity et al., 2011). Generally, the 
increased temperature can exert diverse, both pro- and anti-
inflammatory effects on macrophage function, a phenomenon 
that was reviewed in detail by Lee and Repasky. The authors 
proposed that the cytokine response induced by a mild heat 
treatment is largely influenced by the specific activation stage of 
the macrophage cells (Lee and Repasky, 2012).
It is well known that age-related processes or disease conditions 
can alter the cellular protein homeostasis. The accumulation 
of misfolded proteins increases constantly in the brain during 
aging, and probably, this leads to the elevation of the basal HSP 
level found in different brain regions (Sőti and Csermely, 2000). 
For example, higher level of HSPB1 and HSPA1 were detected 
in the olfactory bulb of middle-aged and old rats compared 
to young ones (Crum et al., 2015). The basal expression of 
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HSPA1 was significantly higher in the cortex of old mice as well 
(Carnemolla et al., 2014). Interestingly, this study also describes a 
downregulation of HSPB1 in the striatum of old mice (Carnemolla 
et al., 2014) while others found an age-related increase in HSPB1 
level in the striatum, subtantia nigra, and cortex of rats (Gupte 
et al., 2010; Gleixner et al., 2014). On the other hand, the heat-
shock response and the inducibility of HSPs decline during aging 
and in disease conditions (Sőti and Csermely, 2000; Calderwood 
et al., 2009). Such decrease in the activation of HSF1 and thus in 
the stress inducibility of HSPs might appear in several conditions 
as it was observed during a DNA damage–initiated senescent 
program (Kim et al., 2012). The mouse model of HD has also been 
described to have a reduced heat-shock response (Neueder et al., 
2017). An age-associated decrease in HSF1 activation has been 
observed in several studies: HSF1 activation reduced with age in 
rat hepatocytes (Heydari et al., 2000) and Caenorhabditis elegans 
neuronal cells also showed a significant age-associated decrease 
in HSF1 activation (Kern et al., 2010). Alterations in nutritional 
lipid supplies were also associated with a reduced heat-shock 
response in parallel with a marked decrease in the proportions of 
n-3 and n-6 polyunsaturated fatty acids (Péter et al., 2012). Also, 
a high-cholesterol diet–induced hyperlipidemia was described 
to attenuate the expression of HSPA1 following either heat or 
ischemic treatment in rat hearts (Csont et al., 2002). Based on 
these results, it is tempting to hypothesize that the impairment 
in HSF1 activation may not only cause a disturbed protein 
homeostasis but also an uncontrolled inflammatory process. 
Unregulated inflammation in the CNS during aging might 
contribute to the pathogenesis of neuronal diseases. Therefore, 
restoration of the heat-shock response and the HSF1 activity may 
help to delay age-related changes in the brain.
HSPs and Their Role in CNS Diseases
The expression of HSPs could rapidly increase in response to 
different acute brain injuries, such as ischemic stroke (Sharp 
et al., 2013). For example, HSPA1 expression is increased in 
microglia, astrocytes, and endothelial cells in the infarct area, 
while it is elevated mainly in neurons in the penumbra (Sharp 
et al., 2000). In contrast, protein levels of HSPB1 are increased 
almost exclusively in astrocytes and to a lesser extent in certain 
neurons in the ischemic brain tissue following middle cerebral 
artery occlusion, and it is thought to stabilize the astrocyte 
cytoskeleton by binding to GFAP under stress conditions (Sharp 
et al., 2013). However, another study found that HSPB1 and 
HSPB5 showed a high level of expression after an ischemia/
reperfusion injury and that this expression profile was mainly 
associated with neurons in the infarcted cortex rather than 
glia cells. It was also shown that HSPB1 and HSPB5 were 
phosphorylated after ischemia, proposing that phosphorylation 
can affect their neuroprotective role (Bartelt-Kirbach et al., 2017). 
Moreover, HSPs have been found to be associated with toxic 
protein accumulations in protein-misfolding neurodegenerative 
diseases like AD, PD, and HD. HSPB1 and HSPB5 were detected 
in senile plaque-associated astrocytes in the brain of patients with 
AD (Wilhelmus et al., 2006a). Moreover, an in vitro binding of 
HSPB1 to hyperphosphorylated tau, purified from AD brain, has 
also been observed (Shimura et al., 2004). HSPB5 was shown to 
co-localize with α-synuclein in the Lewy bodies and to strongly 
inhibit the elongation of the α-synuclein fibrils (Waudby et al., 
2010). Swaroop et al. described an elevated expression for HSPD1 
and Il-1β in a study which performed gene expression analysis on 
human brain samples affected with various CNS diseases such as 
AD, PD, stroke, or infections (Swaroop et al., 2018).
HSPs have been shown to be neuroprotective in many 
acute and chronic pathological conditions affecting the brain; 
therefore, they are considered as potential therapeutic targets 
(reviewed in: Tóth et al., 2015; Penke et al., 2018; Carra et al., 
2019). For example, induced expression of HSPA1 in APP/PSEN1 
mice decreased the level of inflammatory cytokines (Sun et al., 
2017), whereas transgenic overexpression of HSPA1 or HSPB1 
in mouse models of AD was able to reduce Aβ plaque formation 
and cognitive dysfunctions (Hoshino et al., 2011; Tóth et al., 
2013) In addition, HSPB8 can promote motor neuron survival 
by diminishing the toxic effects of dipeptide repeat proteins 
(Cristofani et al., 2018; Zhu and Reiser, 2018). Current studies 
revealed that the inhibition of HSPC1 can ameliorate the 
symptoms of neurodegenerative diseases through inducing 
the activation of HSF1 and HSPA1, as well as the clearance of 
protein aggregates (Thirstrup et al., 2016; Wang et al., 2017). 
Elevated levels of small HSPs are able to ameliorate neuronal 
cell death under acute brain-damaging conditions as well, like 
cerebral ischemia and ethanol administration (Tóth et al., 2010; 
van der Weerd et al., 2010; Arac et al., 2011). Furthermore, HSPA1 
overexpression improved the outcome of stroke by preventing 
neuronal apoptosis (Kim et al., 2016).
As molecular chaperones, the main role of HSPs is to 
suppress the aggregation of misfolded toxic proteins, which can 
explain their protective effects in protein-misfolding disorders, 
like AD or PD. HSPB1 and HSPB5 were found to bind to Aβ, 
inhibiting its fibril formation, therefore reducing its cytotoxic 
effect in cerebrovascular cell culture in vitro (Wilhelmus et al., 
2006b). HSPB1 and HSPB5 were also shown to interact with 
the aggregation-prone α-synuclein to prevent its aggregation 
in vitro (Cox et al., 2016). Baughman et al. revealed that both 
HSPB1 and HSPA8 are able to prevent the formation of toxic 
tau fibrils. HSPB1 can transiently interact with tau during the 
early phase of fibril formation, while HSPA8 binds to tau tightly 
at later stages (Baughman et al., 2018). This data indicates that 
these HSPs might complement each other’s function under stress 
conditions. To restore protein homeostasis, HSPs can also aid the 
degradation of misfolded proteins via the ubiquitin-proteasome 
system or by autophagy, to prevent their accumulation in the 
brain. According to earlier results, under ischemia-induced 
hypoxia, the level of chaperone-mediated autophagy, which 
specifically degrades the HSPA8 target proteins, was enhanced 
which was beneficial for cell survival (Dohi et al., 2012). 
Another study describes HSPB8 and HSPA8 as part of a multi-
protein complex responsible for selectively removing aggregated 
proteins in amyotrophic lateral sclerosis (Crippa et al., 2010). It 
was demonstrated that the collaboration between HSPB8 and 
the co-chaperone BAG3 can enhance autophagy and thereby 
increase the clearance of protein inclusions produced in motor 
neuron diseases (Crippa et al., 2016).
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Aside from their classical chaperone function, it has 
been shown that HSPs have multiple functions within a cell 
(Horváth et al., 2008; Lanneau et al., 2008; Miller and Fort, 
2018). In addition to their central role in the regulation of 
protein homeostasis, HSPs may exert neuroprotection through 
several non-chaperone functions (Tóth et al., 2015). For 
example, neuronal cultures from the hippocampus of mice 
overexpressing HSPB5 were shown to be able to sustain their 
dendritic structures upon heat shock (Bartelt-Kirbach et al., 
2016) suggesting a role in preserving the dendritic structure 
and neuronal connectivity upon stress. Numerous data confirm 
that HSPs can also protect cells against oxidative stress, which 
is increased in acute and chronic neurodegenerative conditions. 
This function of HSPs seems to be independent of their anti-
aggregation effect in certain cases (Wyttenbach et al., 2002). 
Moreover, HSPs have been demonstrated to inhibit apoptotic cell 
death cascades triggered by toxic, aggregation-prone proteins, 
like α-synuclein or Aβ (Zourlidou et al., 2004, Yurinskaya et al., 
2015). HSPs can also exert their beneficial role through the 
protection of the BBB, the damage of which was associated with 
many CNS diseases (Sweeney et al., 2019). HSPB1 expressed in 
endothelial cells prevented the BBB disruption and immune cell 
infiltration by stabilizing the junctional proteins and inhibiting 
actin polymerization after ischemia (Shi et al., 2017). Moreover, 
phosphorylated recombinant HSPB1, which was administered 
intravenously after ischemic injury, was also found to be effective 
in preventing severe BBB damage (Shimada et al., 2018).
All these activities of HSPs could have an alleviating effect 
on the pro-inflammatory milieu associated with neurological 
diseases. By the reduction of neuronal cell death and protein 
aggregation, HSPs might preclude the initiation of inflammation. 
By preserving the integrity of the BBB, they might constrain the 
infiltration of peripheral immune cells. However, an emerging 
number of evidence support that HSPs, especially extracellular 
HSPs, directly interact with immune cells. The next chapter of 
the review is aiming to describe this phenomenon in more detail.
Extracellular HSPs
Historically HSPs have been regarded as intracellular molecules 
but, in the last decades, it was revealed that they can also occur 
in the extracellular space (reviewed in: van Noort et al., 2012; 
Giuliano et al., 2011; De Maio and Vazquez, 2013; Calderwood, 
2018; Reddy et al., 2018). Many different cell types have been 
shown to be able to secrete HSPs. The first studies describing 
extracellular HSPs were performed on squid glial cells (Tytell 
et al., 1986) and rat embryonal cell cultures (Hightower and 
Guidon, 1989). Tumor cells also secrete high amount of HSPA5 
(Kern et al., 2009), HSPC3 (Suzuki and Kulkarni, 2010), or 
HSPB1 (Stope et al., 2017), and HSPB5 was detected in the 
media of cultured human adipocytes as well (Lehr et al., 2012). 
Thermal stress has been demonstrated to increase the amount 
of secreted HSPA1 from astrocytes (Taylor et al., 2007) and 
HEPG2 cells (Vega et al., 2008). Moreover, a recent study showed 
the release of phosphorylated HSPB1 from aggregating human 
platelets (Tokuda et al., 2018). Therefore, we can suppose that 
stress protein release may have important regulatory roles under 
physiological and pathological conditions (Calderwood et al., 
2007). One possible mechanism of HSP release is the lysis of 
damaged, necrotic cells. Several HSPs such as HSPA1, HSPC1, 
DNAJ, or HSPB1 were found in the supernatant of E.G7 mouse 
T-lymphocytes (Basu et al., 2000) or HeLa cells (Saito et al., 2005) 
after the induction of necrotic cell death by freeze-thaw cycles. 
First, it was assumed that this is the only way for HSPs to be released 
from a cell. If we suppose that necrotic cells are the main source 
of extracellular HSPs, the presence of HSPs in the extracellular 
environment would indicate tissue damage. However, this cannot 
explain the selective release of HSPs even under non-lethal, mild 
stressful conditions when cell death is not significantly present. 
For example, a physiological, fever range heat treatment was 
able to induce HSPA1 release from prostate carcinoma cells 
(Mambula and Calderwood, 2006). Cardiac myocytes secrete 
HSPD1 even under unstressed conditions; however, a mild 
hypoxic stress further increased the amount of HSPD1 released 
without signs of necrotic cell death (Gupta and Knowlton, 2007). 
Similarly, HSPA1 was secreted by purified human peripheral 
blood mononuclear cells under normal culture conditions and 
after heat treatment with a barely detectable cell damage (Hunter-
Lavin et al., 2004). The mechanism of active, controlled release of 
HSPs is unclear as they have no secretion leader signal in their 
sequence and inhibitors of the classical protein transport, and 
secretory pathways cannot prevent HSP secretion. For example, 
brefeldin A which is able to block protein transportation from 
the endoplasmic reticulum to the Golgi seemed to be ineffective 
in arresting HSP release either in the above mentioned studies 
(Hunter-Lavin et al., 2004; Gupta and Knowlton, 2007) or 
in heat-shock-treated Caco-2 cells (Broquet et al., 2003). In 
contrast, HSPA1 release was inhibited by methyl-β-cyclodextrin, 
a chemical that has membrane raft-disrupting effect suggesting 
that the association of HSPA1 with lipid rafts is necessary for its 
secretion (Broquet et al., 2003; Hunter-Lavin et al., 2004). Indeed, 
several non-traditional secretory mechanisms were proposed to 
explain the regulated release of HSPs. Methylamine treatment 
has been demonstrated to block HSPA1 export in different 
cell types. As this compound can increase intra-lysosomal pH, 
it was proposed that the HSP secretion might be mediated by 
secretory lysosomes (Hunter-Lavin et al., 2004; Mambula and 
Calderwood, 2006). This was also supported by the observation 
that heat shock stimulates lysosomal exocytosis and increases 
the HSPA1 level in the lysosomal fraction (Mambula and 
Calderwood, 2006). Co-localization of HSPB1 with a lysosomal 
marker suggests that this sHSP can also be secreted through the 
lysosomal pathway (Rayner et al., 2008; Lee et al., 2012a). As the 
inhibition of exosomal release from cultured cells was shown 
to inhibit the secretion of HSPs, exosomes can be considered 
as another potential carriers for extracellular HSPs (Gupta 
and Knowlton, 2007; Rayner et al., 2009). These small cell-
derived vesicles are generated constitutively by many cell types, 
like immune cells; however, their release is further increased 
in response to cellular interactions or stress conditions. By 
transferring lipids, cytosolic proteins, or RNAs from the donor 
cells, these vesicles can influence the function of acceptor cells; 
therefore, they have important roles in cell–cell communication 
(Campanella et al., 2014; Edgar, 2016). Until today, many studies 
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confirmed  the  presence of different HSPs in exosomal vesicles 
released by cancer cells (Chalmin et al., 2010; McCready et al., 
2010; Stope et al., 2017), primary cortical astrocytes (Nafar et al., 
2016), or by human retinal pigment epithelial cells (Sreekumar 
et  al., 2010). However, it still remains unclear if HSPs are only 
cargo materials in exosomes or they also can act as targeting 
molecules toward the host cells by being localized on the exosomal 
surface. When HSPs were observed to be present only in the 
lumen of exosomes, there was no observable interaction between 
them and the surface receptors of the target cell (Clayton et al., 
2005). In this case, the exosome-delivered HSPs cannot interact 
directly with the target cells only if the vesicles “burst” outside of 
the cell or fuse with the cell membrane, releasing HSPs into the 
extracellular space or into the cytosol, respectively (De Maio and 
Vazquez, 2013). On the other hand, other studies found HSPs 
in a membrane-bound state in exosomes. For example, HSPA1 
has been demonstrated to leave heat-shock-treated HEPG2 
cells in a membrane-associated form (Vega et al., 2008). Also, 
in primary rat cortical astrocytes, Aβ induced the exosomal 
release of HSPB1, which was associated with the membrane of 
the exosomes (Nafar et al., 2016). Tumor cell–derived exosomes 
were found to express HSPA1 on their surface (Gastpar et al., 
2005; Chalmin et al., 2010) which makes it possible to stimulate 
the target cells through surface HSP receptors.
Therefore, it seems that HSPs are released continuously even 
from unstressed cells. Under stress conditions, cells respond to 
injury with a strong increase of HSP expression to cope with stress-
induced impairments like protein denaturation or apoptosis. 
At the same time, cellular stress promotes a subsequent release 
of HSPs into the extracellular space (Calderwood et al., 2007). 
Accordingly, many reports demonstrated the increased level of 
HSPs in body fluids after different stress insults and pathological 
conditions (Quintana and Cohen, 2005; De Maio and Vazquez, 
2013; Reddy et al., 2018). HSPD1 levels in the serum are increased 
in both temporal lobe epilepsy patients and in the animal model 
of the disease in response to seizures, suggesting that plasma 
HSPD1 can be used as a biomarker reflecting neuronal cell 
death (Gammazza et al., 2015). Elevated serum HSPD1 is also 
related to the severity of both acute and chronic heart failures 
(Bonanad et al., 2013). HSPA1 level in the blood seems to be a 
useful biomarker for the detection of different tumor types such 
as pancreatic cancer (Dutta et al., 2012) as well as head and neck 
squamous cell carcinoma (Gehrmann et  al., 2014). Moreover, 
the serum level of HSPA1 is increased in diabetic patients and 
correlates with the severity of the disease (Nakhjavani et al., 
2010). Extracellular small molecular weight HSPs have also 
been associated with different pathological states, as HSPB1 
has been detected in the serum of patients with several types 
of cancer, such as breast cancer (Fanelli et al., 1998; Banerjee 
et al., 2011), hepatocellular carcinoma (Feng et al., 2005), gastric 
adenocarcinoma (Huang et al., 2010), colon cancer (Thuringer 
et al., 2015), or pancreatic carcinoma (Melle et al., 2007; Liao et al., 
2009). Plasma HSPB1 level is increased in chronic pancreatitis 
(Liao et al., 2009), and during acute ischemic stroke conditions 
(Gruden et al., 2013). Myocardial cells were further observed to 
release HSPB1 after ischemia (Jin et al., 2014). Lesion size after 
stroke was found to be strongly correlated with serum HSPB5 
levels in a human study, however, interestingly only in younger 
patients, suggesting that this response is age-dependent (Arac 
et al., 2011). Extracellular HSPs which are released from infected, 
damaged, or stressed cells are able to trigger immune response by 
activating many cells of the innate and adaptive immune systems 
and can act as local “danger signals” that promote stress response 
programs in surrounding cells.
Heat-Shock Proteins and Inflammation 
Modulation
Extracellular HSPs were shown to have a relatively distinct 
role from what was observable as their intracellular action. 
Although, the transmission of HSPs between cells was shown 
to contribute to the maintenance of normal proteostasis under 
non-stress conditions (Takeuchi et al., 2015), HSPs are released 
more substantially from cells under stress conditions. The first 
observation describing the presence of extracellular HSPs 
was already associated with stress when a distinct transfer of 
HSP like proteins was described from glial cells to the axon of 
neuronal cells upon heat stress, in a squid model system (Tytell 
et al., 1986). This study was also among the first to suggest a 
neuroprotective role of stress proteins in the nervous system. 
Later, this phenomenon was shown to be true for mammalian 
cells because human glioblastoma cells were also shown to 
secrete a large amount of HSPA1, and human neuroblastoma 
cells were described to take up exogenously added, purified 
HSPA1 which conferred the neuronal cells with an elevated 
resistance against heat stress and apoptosis (Guzhova et al., 
2001). Evidence from studies into intracellular HSPA1 points 
toward the conclusion that intracellular HSPA1 can exert an 
anti-inflammatory effect in the brain. A study conducted with 
mice overexpressing HSPA1 showed that, during ischemic 
conditions, HSPA1 could exert an anti-inflammatory action 
by the reduction of NF-κB activity (van  Eden et al., 2005). 
Another study also suggested a similar action for HSPA1 
during ischemia as it was able to interfere with the activation 
of NF-κB by inhibiting the phosphorylation IκB by IκB kinase 
(IKK) (Zheng et al., 2008). This was also associated with the 
reduction of microglia-mediated cell death of astrocytes. 
Moreover, decreased DNA-binding activity of NF-κB was 
found in an HSPA1 overexpressing mouse microglial cell 
line in response to TNFα treatment (Sheppard et al., 2014). 
In contrast to the notion that HSPB1 is traditionally viewed 
as a chaperone responsible for acting as a holdase to hand 
over destabilized proteins for the ATP-dependent chaperone 
system, intracellular HSPB1 also provides protection against 
apoptosis by inhibiting mitochondrial apoptotic pathways and 
by facilitating the activation of NF-kB (Concannon et al., 2003; 
Guo et al., 2009). In microglial cells, HSPB1 was shown to 
inhibit the activation of NF-kB and decrease microglial TNF-α 
production by promoting the lysosomal degradation of IKKβ 
by chaperone-mediated autophagy (Liu et al., 2018b). HSPB1 
was also associated with an intracellular anti-inflammation 
modulatory function in epithelial cells, where HSPB1 was able 
to associate with the IKKβ and IKKα and inhibit their activity 
thereby suppressing NF-κB activation (Kammanadiminti and 
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Chadee, 2006). This evidence implies that extracellular HSPs, 
after being taken up by the target cell, may act through a similar 
mechanism which would confer resistance to recipient cells in 
the brain. As mentioned previously, extracellular vesicles may 
fuse with the membrane of target cells, releasing the HSPs which 
are in their lumen into the cytosol of the target cell (De Maio 
and Vazquez, 2013). Therefore, it can be assumed that, similarly 
to intracellular ones, HSPs from extracellular origin might have 
neuroprotective, anti-apoptotic, and anti-inflammatory effects.
On the other hand, extracellular HSPs, either released 
passively from necrotic cells or secreted actively and presented on 
the surface of extracellular vesicles, can bind to several receptors 
of the target cells, influencing immune functions. Indeed, 
many in vitro studies confirmed that the treatment of different 
cell types with exogenous HSP preparations has an impact 
on the cytokine response. HSPA1 treatment of LPS-activated 
monocytes decreased the level of TNF-α and IL-6 (Ferat-Osorio 
et al., 2014). Interestingly, addition of extracellular HSPA1 
to bone marrow–derived murine dendritic cells resulted in a 
reduced basal level of TNF-α and IFN-γ (Borges et al., 2013). In 
contrast, other evidence implies an opposite pro-inflammatory 
role for extracellular HSPA1 as it has been described to promote 
inflammation by the activation of NF-κB and the stimulation 
of human macrophages to secrete pro-inflammatory cytokines 
TNF-α, IL-1β, and IL-6 (Asea et al., 2000). Exogenous HSPA1 can 
increase the production of IL-6 and TNF-α in a concentration-
dependent manner in rat microglial culture as well (Kakimura 
et al., 2002). Moreover, extracellular HSPA1 and HSPC1 are 
involved in the activation of the adaptive immune response. 
By sequestering antigenic molecules, they can help their 
transfer to antigen presenting cells and their load onto MHC 
molecules (reviewed by Calderwood et al., 2007; van Noort, 
2008; Zininga et al., 2018). Compared to HSPA1, the functions 
of other extracellular HSPs, like sHSPs, are relatively less well 
defined despite the fact that they are detected to be present in 
the extracellular environment. Among these proteins, sHSPs are 
intriguing targets to study in the neurobiological context since 
they have already been implicated to act as neuroprotective 
agents in several conditions intracellularly. Considering that 
HSPB1 has been associated with the transcription factor 
NF-kB in many studies, it is tempting to speculate that, among 
the sHSPs, HSPB1 could exert an extracellular control over 
inflammatory processes in the brain. The extracellular release 
of HSPB1 has been suggested to have a role in modulating the 
immune response around the cell, as extracellular HSPB1 was 
found to activate NF-κB in macrophages (Salari et al., 2013) and 
myocardial cells (Jin et al., 2014). HSPB1 has been demonstrated 
to increase the level of IL-8 while inhibiting the production of 
TGF-β1 CD40 ligand in astrocytes in vitro (Bruinsma et al., 2011). 
The treatment of microglia cultures with α-crystallin resulted in 
the activation of the cells and increased the production of nitric 
oxide and TNFα (Bhat and Sharma, 1999). On the other hand, 
another study showed that α-crystallin pretreatment can reduce 
the level of the same molecules induced by LPS in primary rat 
microglial cell culture (Wu et al., 2009). Moreover, it effectively 
reduced astrocyte activation in vitro, in response to LPS treatment 
(Masilamoni et al., 2006).
These results clearly show that HSPs are involved in the 
regulation of immune responses in different organs, including 
the brain. However, whether their exact effect is anti- or 
pro-inflammatory, it depends on many factors (Figure 2). 
An interesting observation came from by Basu et al. that 
necrotic but not apoptotic cells are able to release HSPA1, 
HSPC1, and calreticulin which were found to be immune-
stimulatory through the activation of antigen-presenting cells 
via the NF-κB pathway (Basu et al., 2000). This result suggests 
that the effect of the released HSP is highly dependent on the 
state of the donor cell and the cellular processes taking place 
therein. For example, as described in the “extracellular HSP” 
section, aside from the active vesicular secretion, HSP could be 
excreted passively, by necrosis. The emergence of the seemingly 
contradicting observations describing HSPA1 both as a pro- and 
an anti-inflammatory agents have led to the hypothesis that the 
context as to how HSPA1 (and possibly other HSPs) reaches the 
extracellular environment matters in regard to their modulatory 
action on inflammation (Broere et al., 2011; van Eden et al., 2012). 
However, probably not the donor cell’s state is the only factor that 
can influence the effect of HSPs. Similarly, as was proposed in the 
case of heat treatment (Lee and Repasky, 2012), we can suppose 
that the HSPs themselves might have diverse effects based on the 
status of the recipient cell.
Moreover, several receptors have been characterized for HSPs 
which can all turn on specific signaling pathways. This suggests 
that the anti- or pro-inflammatory roles of HSPs are strongly 
dependent on their cell surface receptors as well. HSPs exert their 
immunomodulatory functions on macrophages, dendritic cells, 
T cells, B cells, and NK cells via many different receptors (reviewed 
in Quintana and Cohen, 2005; Calderwood et al., 2016). For 
example, CD91, CD40, and the chemokine receptor CCR5 have 
been demonstrated to interact with HSPA1 (Basu et al., 2001; 
Becker et al., 2002; Pido-Lopez et al., 2007), of which CD40 and 
CCR5 are expressed on the surface of microglial cells. Scavenger 
receptors such as LOX-1 and SREC-1 can act as receptors not 
only for HSPA1 but for HSPD1 and HSPC1 as well (Thériault 
et al., 2006; Murshid et al., 2010; Xie et al., 2010a). Two members 
of the TLR family, namely, TLR 2 and TLR4, are considered as 
HSP receptors; however, their specific interactions have hitherto 
been questioned. As the same receptors are responsible for the 
detection of bacteria-derived danger signals, like LPS, it seems 
to be possible that the cytokine induction was not caused by the 
HSPs themselves rather by the co-purified bacterial endotoxins 
(reviewed in Quintana and Cohen, 2005; van Noort, 2008; Kim 
and Yenari, 2013). However, later several studies demonstrated 
that non-bacteria-derived HSP preparations can also induce 
macrophage activation (Basu et al., 2000; Wang et al., 2006; Vega 
et al., 2008). These studies also draw attention to the probability 
that sequestering of different molecules by HSPs could play a 
role in their physiological immunomodulating effect. HSPs are 
able to bind to a broad array of molecules from bacterial LPS 
to tumor-derived peptides, augmenting their immunogenicity 
(Quintana and Cohen, 2005). This was confirmed by a study 
demonstrating that HSPD1 and HSPA1 alone were inefficient to 
induce the TNF-α secretion of human peripheral blood–derived 
mononuclear cells; however, they can potentiate LPS-induced 
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TNF-α release when added 24h prior to the stimulation (Bangen 
et al., 2007). It is likely, that other, yet uncharacterized receptors 
exist through which the immunomodulatory effects of HSPs 
could be mediated. Furthermore, the combinatorial effect of the 
different cell surface receptors might influence the exact pro-or 
anti-inflammatory role of certain HSPs (Calderwood et al., 2016).
It is also important to note that based on changes in the amount 
of a single cytokine, it is not possible to determine clearly if a 
process is pro- or anti-inflammatory. For example, TNF-α seems 
to have a dual role in neuroinflammation and can be involved 
in both pro- and anti-inflammatory response profiles (van Noort 
et  al., 2012). Therefore, measuring the levels of only a few 
cytokines in a certain isolated cell line is probably not sufficient to 
determine the overall biological effect of a treatment (van Noort 
et al., 2012). The situation is further complicated by the fact that 
the inflammatory process itself may have beneficial and harmful 
outcomes as well. Therefore, to determine the role of HSPs in 
inflammatory brain diseases, we should take into consideration 
several symptoms not only the level of inflammatory factors.
Results suggest that exogenously added HSPs have a general 
anti-inflammatory effect in different acute brain injuries. 
Several evidences support the potential neuroprotective role 
of extracellular HSPA1 since it was described to inhibit motor 
and sensory neuronal cell deaths after traumatic nerve injury 
FIGURE 2 | Diverse effects of HSPs on inflammation. The exact role of HSPs in the regulation of innate and adaptive immune responses is influenced by several 
factors. Transcription of HSP genes is regulated by HSF1, which normally presents in the cytosol in its inactive form bounded to HSPs. Under stress conditions, 
the monomeric HSF1 dissociates from HSPA/C, trimerizes, and subsequently translocates to the nucleus, where it upregulates the expression of HSPs. Moreover, 
HSF1 was suggested to have bi-directional effect on the expression of inflammatory factors. HSF1 was shown to inhibit the expression of TNF-α by binding to 
its promoter, while it was also able to activate TNF-α as part of a multiprotein complex. Similarly, HSF1 was found to bind directly to IL-6 promoter opening of the 
chromatin structure thereby facilitating the access of activator or repressor molecules. The newly synthesized intracellular HSPs have protective and anti-apoptotic 
effects. Both HSPB1 and HSPA1 were shown to inhibit the activation of NF-κB by inhibiting IKK, thereby exerting an anti-inflammatory function. At the same time, 
cellular stress promotes the release of HSPs into the extracellular space. Lethal stress leads to the passive secretion of HSPs from necrotic cells, which usually 
induce a strong pro-inflammatory activity. On the other hand, HSPs can be secreted actively even under non-lethal, mild stress conditions. Although the classical 
protein secretory pathways are not secreting HSPs, alternative secretory mechanisms, such as exosomal release can be the basis of their regulated export. HSPs 
were found in the lumen of exosomal vesicles or they can occur in a membrane-associated form. Luminal HSPs cannot interact directly with the target cells only 
if the vesicles “burst” outside of the cell or fuse with the cell membrane, releasing HSPs into the extracellular space or into the cytosol. HSPs presented in the 
membrane of extracellular vesicles can bind to various surface receptors, such as toll-like receptors, that can induce the NF-κB pathway. Moreover, by sequestering 
antigenic molecules, HSPs are involved in antigen presentation. On the other hand, many studies confirmed that exogenous HSPA1 and HSPB1 exert anti-
inflammatory effects through yet undefined mechanism in different pathological conditions. (Reviewed in van Noort, 2008; De Maio and Vazquez, 2013; Kim and 
Yenari, 2013). Red arrows denote pro-inflammatory, while blue arrows denote anti- inflammatory processes.
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(Tidwell et al., 2004) and to preserve synaptic transmission during 
hyperthermic conditions (Kelty et al., 2002). The exogenous 
addition of HSPA8 was also shown to prevent axotomy-induced 
death of sensory neurons (Houenou et al., 1996). The injection of 
recombinant HSPB1 exerted a protective effect against ischemic 
injury and decreased inflammation in the brain during these 
processes (Shimada et al., 2018). Apart from HSPB1, another 
sHSP, HSPB5 was also described to have an anti-inflammatory 
role when applied extracellularly whereby it acted against 
pathologic CNS inflammation in autoimmune demyelination 
and ameliorated experimental autoimmune encephalomyelitis 
in mice (Ousman et al., 2007). Intraperitoneal injection of 
recombinant HSPB5 was able to reduce lesion size and modulate 
the peripheral inflammatory response, even when the treatment 
was started 12 h after stroke onset (Arac et al., 2011). HSPB4/
B5 isolated from bovine lens prevented the elevation of GFAP 
and NF-κB expression induced by acute inflammation in the 
brain of silver nitrate–treated mice (Masilamoni et al., 2006). 
Intravitreal injection of α-crystallin decreased the expression of 
TNFα and iNOS after optic nerve injury in vivo in rats (Wu et al., 
2009). In contrast, the intrathecal injection of HSPD1 activated 
the TLR4 pathway which resulted in neurodegeneration and 
demyelination (Rosenberger et al., 2015). Furthermore, another 
microglial receptor, LOX-1, was described to bind to HSPD1 and 
to promote a deleterious inflammatory process (Zhang et al., 
2012). HSPD1 is originally localized to the mitochondria but, in 
the case of brain injury, it was also found to be present in the 
extracellular space. This extracellular presence is due to the fact 
that, during CNS disorders, mitochondria dysfunction occurs, 
leading to the abnormal distribution of HSPD1 (Cappello et al., 
2010). The extracellular HSPD1 can serve as a danger signal, and 
in cell cultures, it was shown to induce neuronal damage which 
was associated with the TLR4-MyD88 signaling pathway in 
microglia cells (Lehnardt et al., 2008).
Numerous evidences support the protective role of HSPs in 
chronic neurodegenerative diseases in vivo, especially in protein-
misfolding disorders, described briefly in the section “HSPs 
and their role in CNS diseases.” However, most of these studies 
were performed on transgenic animals overexpressing different 
HSPs, or the increased expression of HSPs was induced by drug 
treatment. Therefore, it is difficult to separate the specific effects 
of intra- and extracellular HSPs, although one can suppose that 
both are involved in ameliorating the symptoms. For example, 
in a Drosophila model, it was demonstrated that HSPA, 
secreted into the extracellular space, can bind to Aβ reducing its 
neurotoxic effect and therefore the level of cell death (Fernandez-
Funez et al., 2016). In contrast, it is difficult to find studies in 
which exogenously added HSPs are used to treat chronic 
neurodegenerative diseases in animal models. Nonetheless, 
several results suggest that the neuroprotective effect of HSPs is 
partly based on their ability to influence the function of immune 
cells. Microglial cells activated by exogenous HSPA1 or HSPC1 
showed an elevated capacity for Aβ phagocytosis suggesting 
that extracellular HSPs might facilitate the clearance of these 
misfolded proteins (Kakimura et al., 2002). This effect of HSPC1 
was confirmed later in vivo as well, by the simultaneous intra-
hippocampal injections of Aβ and HSPC1 (Takata et al., 2003). 
HSPD1 was also found to stimulate phagocytosis in the N9 murine 
microglial cell line. Interestingly, this effect was diminished by 
the downregulation of TREM2 receptor. As HSPD1 was found to 
bind to TREM2, it is likely that the HSPD1-induced activation of 
phagocytosis might be mediated through this receptor (Stefano 
et al., 2009). As the decline of the normal phagocytic activity 
might have an important role in the pathogenesis of diseases 
associated with protein misfolding (see details in “Role of 
neuroinflammation in different acute and chronic CNS diseases” 
section), the promotion of the engulfment of toxic proteins by 
microglial cells might be useful in the treatment of these diseases. 
Therefore, HSPs could be important therapeutic targets in both 
acute and chronic neurological diseases, not only because of their 
classical chaperone function, but also considering their ability to 
modulate inflammatory processes.
Modulation and Application of Heat-Shock 
Proteins as Potential Therapies Against 
Chronic Neuroinflammation
Based on the accumulated evidence reviewed herein, HSPs 
themselves and compounds modulating the heat-shock response 
could potentially open up new avenues for inflammation 
modulation in the nervous system. Approaches to fine-tune 
the intracellular amount of HSPs and to deliver functional, 
therapeutic extracellular HSPs to cells are on the rise and would 
certainly contribute to the panel of medical treatments against 
inflammation-associated diseases in the nervous system. For 
this purpose, membrane lipid therapy seems to be a promising 
solution, as membrane fluidity and microdomain organization 
are involved in the regulation of the cellular heat-shock response. 
For example, manipulating membrane lipid composition can 
influence the release, and therefore the immune stimulatory 
effects, of HSPs (Vigh et al., 2007). An emerging number of studies 
are describing the manipulation of HSPs by chemical means 
(Török et al., 2014). HSP co-inducers were already successfully 
applied in mice against hypoxia-induced brain damage (Xu et al., 
2011), chemotherapy-induced peripheral neuropathy in rats 
(Bárdos et al., 2003), and were shown to have neuroprotective 
effects in a mouse model of AD (Kasza et al., 2016). Arimoclomol, 
a drug which acts like an HSP co-inducer, was suggested as a 
candidate for the therapy of amyotrophic lateral sclerosis as it can 
improve hind limb muscle function and motoneuron survival 
in a mouse model of the disease (Kieran et al., 2004; Phukan, 
2010). Arimoclomol was also been demonstrated to have a 
beneficial effect against the neuronopathic form of Gaucher 
disease, by the induction of the HSPA5 (Fog et al., 2018). The 
pharmacological enchantment of the unfolded protein response 
and the heat-shock response by arimoclomol also provided 
protection against retinal degeneration in the animal model 
of rhodopsin retinitis pigmentosa (Parfitt et al., 2014). It is 
important to note that arimoclomol was described to be non-
toxic in a double-blind, placebo-controlled trial in which patients 
with amyotrophic lateral sclerosis received the drug (Benatar 
et al., 2018). BRX-220, another HSP co-inducer, was shown to 
protect motoneurones from axotomy-induced cell death and 
affect the upregulation of HSPC1 and HSPA1 in parallel, in glia 
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and neuron cells (Kalmar et al., 2002). The same compound was 
also observed to be effective in the prevention against peripheral 
neuropathy (Kürthy et al., 2002) and to promote restoration of 
morphological and functional properties in the sensory system 
following peripheral nerve injury (Kalmar et al., 2003).
Geranylgeranylacetone, an HSP inducer, was demonstrated to 
alleviate cerebral ischemic damage in the brains of rats (Uchida 
et  al., 2006). Similar observations were made with respect to 
α-lipoic acid, a heat-shock response activator, in the gerbil brain 
following ischemic stress (Lee et al., 2012b). Pharmacological 
induction of HSPA1 in microglia and neurons by 17-N-allylamino-
17-demethoxygeldanamycin (17-AAG) was shown to reduce the 
volume of hemorrhage and improve neurobehavioral outcomes 
in a mouse model of experimental traumatic brain injury 
(Kim et  al., 2015). Another HSP inducer celastrol, a chemical 
compound isolated from the Celastracea family of plants, was 
identified to induce the phosphorylation and DNA binding of 
HSF1, which consequently can result in the upregulation of 
several HSPs (Westerheide et al., 2004). The fact that celastrol can 
activate heat-shock gene transcription alone or synergistically 
with other stresses or compounds makes it a promising adjuvant 
drug candidate (Westerheide et al., 2004). Celastrol treatment 
was shown to increase the expression of HSPA1 and reduce the 
levels of TNF-α in spinal motor neurons and contribute to motor 
neuron survival in the SOD1(G93A) transgenic mouse model 
of amyotrophic lateral sclerosis (Kiaei et  al., 2005). Other drugs 
with herbal origins have been also shown to act like HSP inducers. 
Paeoniflorin, a monoterpene glycoside, was characterized to 
induce HSP through the activation of HSF1 and the formation of 
HSF1 containing granules in the nucleus (Yan et  al., 2004). The 
treatment of rats with paeoniflorin can protect the brain from 
cerebral ischemic injury via inhibition of apoptosis (Zhang et al., 
2015). Glycyrrhizin a triterpenoid saponin was also suggested to 
be an HSP co-inducer (Yan et al., 2004). Several other compounds 
have been known to have a positive effect on HSP expression such 
as the hydroxylamine derivative HSP co-inducer bimoclomol 
(Vígh  et al., 1997), the antiulcer drug geranylgeranylacetone 
(Hirakawa et al., 1996) or the benzoquinone antibiotic herbimycin 
A (Morris et al., 1996). All of which were being effective against 
different pathophysiological conditions in the CNS, as bimoclomol 
proved to be cytoprotective for retinal glia and neuronal cell 
against diabetes-related ischemic cell damages (Bíró et al., 1998), 
while geranylgeranylacetone is described to be neuroprotective 
against traumatic brain injury (Zhao et al., 2013), and herbimycin 
A treatment was capable to induce sympathetic neuron survival 
and to protect against hypoxia-induced neuronal damage (Cabral-
da-Silva et al., 2003).
Aside from the pharmacological modulation of their 
intracellular expression levels, HSPs themselves can be used as 
therapeutic agents, as described by several studies. Purified HSPA1/
HSPA8 proteins injected into the third ventricle of the brain were 
found to infiltrate into the cytosol of the neurons in different brain 
regions. In parallel, the treatment was able to decrease the duration 
and severity of chemically induced seizures and reduce muscle 
tonus (Ekimova et al., 2010). Similarly, intranasally injected 
human HSPA1 rapidly penetrate into the brain showing mainly 
intracellular localization  (Bobkova  et  al.,  2014). Furthermore, 
exogenous recombinant HSPA1 ameliorates symptoms of AD 
such as Aβ accumulation and memory deficits (Bobkova et al., 
2014) and improves cognitive functions and increases lifespan 
of old mice (Bobkova et al., 2015). The administration of 
recombinant HSPA1 to glioblastoma cells within the brain of rats 
has also shown to alter the inflammatory environment within the 
surrounding region of the tumor as it has induced the activation 
and IFNγ-secretion of CD8+ cells (Shevtsov et al., 2014). These 
studies are highlighting the therapeutic potential of the exogenous 
delivery of recombinant HSPs into the nervous system. However, 
the delivery and targeting of these molecules into the specific 
brain regions could present a significant challenge.
The aforementioned and well-characterized interaction of 
HSPs with membranes (Horváth et al., 2008) might open up new 
possibilities to come across the biological barriers preventing the 
efficient delivery of biological molecules to the brain with a goal 
to achieve the beneficial modulation of inflammatory processes. 
Several HSPs were found to interact and be inserted into the 
plasma membrane, as well the release of HSPs to the extracellular 
environment is associated with membranes (Balogi et al., 2019). 
Thus, it is plausible that the therapeutic application of membrane-
bound HSPs could significantly enhance their anti- or pro-
inflammatory activity. HSPA1 was described to be released into 
the extracellular environment upon heat stress in a membrane-
associated form originating from the plasma membrane also the 
membrane-bound HSPA1 showed a significantly higher potential 
to induce TNF production in macrophages compared to the free 
recombinant form of the protein (Vega et al., 2008). Similarly, other 
observations have detected that exosome containing HSPA1 on 
their surface can stimulate the migration and cytolytic activity of 
NK cells (Gastpar et al., 2005). Membrane-bound HSPA1 was also 
associated with the stimulation of a type 1 CD4(+) helper T cell 
and a CD8(+) cytotoxic T lymphocyte response (Xie et al., 2010b).
Extracellular membranous vesicles as exosomes have already 
been associated with neuroinflammation (Gupta and Pulliam, 
2014). The liposomal delivery of protein into the nervous system 
has also recently been utilized to alleviate inflammatory processes 
(Vieira and Gamarra, 2016). However, the insertion of proteins 
to the bilayer is presenting a significant challenge during the 
preparation of liposomes. This problem can be circumvented 
by the application of a novel form of nanoparticles termed as 
membrane nanodisks, where a lipid bilayer is surrounded by 
an amphipathic protein belt (Rouck et al., 2017). Membrane 
nanodisks are also showed to be potential vehicle for CNS delivery, 
as it has been described to cross the BBB and to effectively target 
glioma cells within the brain (Wang et al., 2018b). The application 
of these membrane nano-carriers might provide a useful strategy 
to deliver membrane-bound HSPs to the nervous system. The 
use of membrane nanodisks in therapy seems to be especially 
promising in the light of the of the fact that the highly tunable lipid 
environment could provide a milieu to the membrane-associated 
proteins which keeps them in solution without the use of detergents 
and maintain a structure which is more similar to the one they 
have when associated with biological membranes (Bayburt et al., 
1998; Dominik and Kossiakoff, 2015). The reconstruction of a 
combination of antigens into membrane nanodisks has already 
been shown to generate protective immunity against viral 
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challenge (Bhattacharya et al., 2010) and to raise anti-cancer 
immunity in mice (Kuai et al., 2017). Thus, the use of these 
membrane mimicking nanodisks to carry HSPs could provide a 
potential new formulation for HSP-based therapies.
CONCLUSION
Immediately after an acute brain injury or infection, inflammation 
contributes to the efficient immune response, eliminating 
cellular debris and pathogens as a precursor to permitting tissue 
repair and regeneration. Similarly, in chronic neurodegenerative 
diseases, such as protein-misfolding disorders, immune cells 
can contribute to the elimination of toxic protein aggregates, 
at least in the initial phase. However, the long duration of the 
triggering stimuli results in excessive, chronic inflammation 
and uncontrolled macrophage activation finally contributing 
to further tissue injury and disease progression. Therefore, 
inflammatory processes should be tightly regulated to maintain 
the balance between remediation and the over-activated, harmful 
effects of the immune cells. Pharmacological manipulation 
of HSP expression, activity and localization might provide an 
opportunity to modulate beneficially the inflammatory processes 
in the brain. Thus, it seems rational to expect that the application of 
compounds with known HSP modulatory activity gradually will 
be tested for their applicability in the field of neuroinflammation. 
Alternatively, the delivery of HSP proteins to the disease-affected 
brain regions could also be expected to be exploited in future 
therapies. However, it is important to note that the full range of 
cell surface receptors functioning as HSP binding partners is not 
elucidated yet. Thus, aside from the technological implications 
of the delivery of the proteins, the proper surface receptor 
interactions and their physiological consequences should be 
appropriately evaluated for each brain area.
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